Once-daily tedizolid is not inferior and has a similar adverse effect profile to twice-daily linezolid in the treatment of acute bacterial skin infections and skin-structure infections, according to results from a phase 3 study called the TR-701 FA vs Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infections (ESTABLISH-2) trial, published online June 6 in Lancet Infectious Disease.
Drug-resistant bacterial infections caused by Gram-positive bacteria have emerged as a major public health problem. Methicillin-resistant Staphylococcus aureus (MRSA) infections, in particular, have high rates of treatment failure, whereas the limitations of current antibiotics have created a need for new drugs, the authors write. Tedizolid is a new antibiotic with improved activity against Gram-positive bacteria such as MRSA, as well as vancomycin- and linezolid-resistant strains.
Source: Veronica Hackethal, MD, Medscape News [6/10/14]